CRINO', Lucio
 Distribuzione geografica
Continente #
NA - Nord America 3.069
EU - Europa 2.261
AS - Asia 925
SA - Sud America 11
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.269
Nazione #
US - Stati Uniti d'America 3.057
IE - Irlanda 598
SG - Singapore 417
IT - Italia 396
SE - Svezia 384
UA - Ucraina 271
VN - Vietnam 169
FI - Finlandia 168
HK - Hong Kong 164
RU - Federazione Russa 132
CN - Cina 115
DE - Germania 108
FR - Francia 60
GB - Regno Unito 46
KR - Corea 36
CH - Svizzera 23
AT - Austria 14
NL - Olanda 12
RO - Romania 12
BR - Brasile 11
BE - Belgio 8
CA - Canada 8
CZ - Repubblica Ceca 8
PL - Polonia 8
GR - Grecia 7
UZ - Uzbekistan 7
LB - Libano 6
IN - India 5
TR - Turchia 5
MX - Messico 4
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
DK - Danimarca 1
HU - Ungheria 1
MD - Moldavia 1
NG - Nigeria 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 6.269
Città #
Chandler 628
Dublin 598
San Mateo 345
Singapore 306
Boardman 225
Dong Ket 169
Hong Kong 164
Santa Clara 159
Andover 146
Medford 145
Princeton 143
Jacksonville 134
Perugia 132
Altamura 129
Lawrence 123
Ann Arbor 107
Wilmington 98
Beijing 61
Saint Petersburg 45
Seoul 36
Norwalk 31
Helsinki 29
San Paolo di Civitate 28
Des Moines 21
Munich 20
Redwood City 16
Ashburn 15
Falls Church 14
Moscow 14
Woodbridge 13
Bucharest 12
Lausanne 11
Los Angeles 10
Dearborn 9
Brussels 8
Den Haag 8
New York 8
Auburn Hills 7
Nuremberg 7
Lappeenranta 6
Simi Valley 6
Shanghai 5
Arezzo 4
Chicago 4
Ottawa 4
Redmond 4
San Diego 4
Tappahannock 4
Vienna 4
Chengdu 3
Costa Mesa 3
Dallas 3
Foligno 3
Frankfurt Am Main 3
Guangzhou 3
Houston 3
Izmir 3
Manassas 3
Marsciano 3
Nanjing 3
Nürnberg 3
Rome 3
Torgiano 3
Toronto 3
Asso 2
Brno 2
Cusano Milanino 2
Faenza 2
Florence 2
Hanover 2
Iglesias 2
Kansas City 2
Mcallen 2
Mexico City 2
Paris 2
Rio de Janeiro 2
Sesto Fiorentino 2
Shenyang 2
Terni 2
Amelia 1
Ankara 1
Azcapotzalco 1
Bologna 1
Bratislava 1
Bristol 1
Brusciano 1
Cheltenham 1
Chieti 1
Chisinau 1
Città Di Castello 1
Clearwater 1
Dudley 1
Duque de Caxias 1
Edinburgh 1
Forlì 1
Frankfurt am Main 1
Genova 1
Giarre 1
Giresun 1
Gravataí 1
Totale 4.315
Nome #
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 101
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 101
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 93
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 86
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 86
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 82
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 80
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 77
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 73
An approach for optimally extending mathematical models of signaling networks using omics data 71
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 70
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 68
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 68
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 67
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 67
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 66
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 66
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 66
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 65
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 64
Non-coding RNAs in lung cancer 64
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 61
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 60
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 60
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 60
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 60
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 59
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 59
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 58
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 58
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 58
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 58
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 58
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 57
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 57
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 57
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 57
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 56
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 56
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 55
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 55
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 55
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 55
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 55
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 54
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 54
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 54
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 53
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 52
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 52
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 52
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 52
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 52
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 52
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 51
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 50
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 50
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 50
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 50
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 49
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 49
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 49
ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors) 47
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 47
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 47
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 47
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 46
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 46
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 46
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 46
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 45
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 45
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 44
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 44
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 44
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 43
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 43
A prospective study on survival in cancer patients with and without venous thromboembolism. 43
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 42
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 41
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 41
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 41
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 41
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 41
Robustness of complex feedback systems: application to oncological biochemical networks 40
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 39
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 39
Risk Stratification Model For Resected Squamous Cell Lung Cancer (r-sqlc) Patients (pts) According To Clinical and Pathological Factors 39
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. 39
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 38
Increased levels of circulating DNA in patients with connective tissue diseases: a possible marker of disease activity in Sjögren’s syndrome 38
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 38
Emerging drugs for small cell lung cancer - an update 37
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. 37
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 37
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 37
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 37
Sunitinib Global Expanded-access Trial In Metastatic Renal Cell Carcinoma (mrcc) - Final Results 36
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study 35
INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 (IGF1R) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION AND EXPRESSION IN SURGICALLY RESECTED NSCLC 34
Totale 5.400
Categoria #
all - tutte 32.351
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.351


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020144 0 0 0 0 0 0 0 15 44 48 13 24
2020/2021975 4 36 50 39 319 79 48 5 99 41 64 191
2021/20221.152 29 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/2025727 43 168 100 47 270 48 32 19 0 0 0 0
Totale 6.550